News

AZD3480 did not meet the trial’s criteria for statistical significance on the primary endpoints, improvement on various cognitive domains measured by the IntegNeuro computerized test battery. AZD3480 was

Complete data are now available from the first stage of the trial, in which patients were randomized 1:2 to receive high-dose cytarabine alone (standard therapy control group) or

The pre-specified primary efficacy endpoint of change in hemolysis was achieved with an 86% reduction. Key secondary endpoints including fatigue and transfusions/anemia were also achieved. In the Aegis

This single-center, double-blind, placebo-controlled, single-ascending dose trial tested the safety, tolerance and pharmacokinetics of a single intravenous administration of NU206, in 32 healthy male volunteers. Participants were enrolled

Dr Schottelius joins MorphoSys from Genentech, South San Francisco, where he served as the director of immunology, tissue growth and repair early development and most recently as medical

Approximately more than 800 subjects have been enrolled in the independent, blind, multicenter study. The company estimates that four to six weeks will be required to allow its

In addition to the new US headquarters facility, Patheon has opened a new pharmaceutical development laboratory in Research Triangle Park. This laboratory will support Patheon’s current US-based pharmaceutical

This study will explore the safety, tolerability and pharmacokinetics of subcutaneous (SC) administration of a bisphosphonate plus recombinant human hyaluronidase enzyme (rHuPH20). Currently, injectable bisphosphonates must be administered

Under the agreement, Symbollon will transfer ownership of its patent application covering use of its technology in the upper respiratory tract. As partial consideration under the agreement, Symbollon